January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
Baricitinib shows promise for treating alopecia areata with mild side effects.
March 2026 in “Lithuanian University of Health Sciences” JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
The THRIVE-AA1 trial evaluated the efficacy of the JAK1/2 inhibitor deuruxolitinib in treating alopecia areata, involving 706 adult patients with significant hair loss. Participants were randomized to receive either a placebo or deuruxolitinib at doses of 8 mg or 12 mg twice daily. By week 24, 29.6% of those on 8 mg and 41.5% on 12 mg achieved a SALT score of 20 or less, indicating substantial hair regrowth compared to placebo. Significant improvements were noted as early as week 8. The treatment was mostly well tolerated, with over 95% of adverse events being mild-to-moderate. The study concluded that deuruxolitinib showed encouraging efficacy for moderate-to-severe alopecia areata.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
37 citations
,
November 2007 in “Journal of Biological Chemistry” Ku80 is a key receptor for Thymosin β4, affecting cell migration and wound healing.
2 citations
,
December 2022 in “Pharmaceutics” The enzyme pyruvate kinase M2 helps hair regrowth and could be a potential treatment for hair loss.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
7 citations
,
November 2023 in “JAAD Case Reports” Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
32 citations
,
April 2019 in “JAAD case reports” JAK inhibitors helped treat hair loss in two people with Down syndrome.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
3 citations
,
October 1994 in “Journal of Dermatological Science” The new antibody, TYHF-1, specifically targets certain hair-related structures.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
Retinoids can help treat skin pigmentation disorders by affecting melanin production.
June 2023 in “jurnal veteriner” The combination of Typhonium flagelliforme extract and natural interferons effectively reduces tumor growth in mice.
12 citations
,
November 2024 in “International Journal of Molecular Sciences” Hydroxytyrosol helps reduce liver injury by blocking certain inflammation pathways.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
April 2024 in “Expert opinion on investigational drugs” JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
September 2025 in “Acta Dermato Venereologica” Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
May 2026 in “Journal of Human Immunity” Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.